Phenotypes associated with this allele
immune system
|
|
• Background Sensitivity: although negative selection of these transgenic thymocytes is stronger on the B6 than NOD background, there is earlier onset and greater penetrance of diabetes in females on the B6 background
• Background Sensitivity: compared with those on the NOD background, on the B6 background these TCR transgenic T cells have greater proliferative response to antigen presentation and display more potent killing of pancreatic islet cells
|
hematopoietic system
|
|
• mice exhibit a complete absence of CD8 T cells expressing the transgenes but transgene-expressing CD4 T cells are present
|
immune system
|
|
• mice exhibit a complete absence of CD8 T cells expressing the transgenes but transgene-expressing CD4 T cells are present
|
|
|
• B2m-deficient female transgenic NOD mice are completely diabetes resistant compared to transgenic NOD controls
|
immune system
|
|
• transgene-expressing female mice develop IDDM with an onset of about 7 weeks of age, whereas CD4-null NOD mice are resistant (no IDDM by 30 weeks of age)
|
hematopoietic system
|
|
• mice exhibit a complete absence of CD4 T cells expressing the transgenes but transgene-expressing CD8 T cells are present
|
immune system
|
|
• mice exhibit a complete absence of CD4 T cells expressing the transgenes but transgene-expressing CD8 T cells are present
|
|
|
• female NOD.scid transgenic mice display accerlerated diabetes development compared to standard NOD females
|
immune system
|
|
• females have a greatly increased rate of diabetes development compared to non-transgenic NOD controls (100% incidence by 6 weeks of age)
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(TcraAI4)1Dvs mutation
(4 available)
Tg(TcrbAI4)1Dvs mutation
(4 available)
|
|
|
immune system
|
|
• T cells expressing the transgenes comprise ~35% of the total peripheral blood lymphocyte population, a significant fraction of these T cells resides in the CD4 lineage rather than in the expected CD8 lineage
|
|
|
• only transgene expressing CD8+ T cells from primary splenocytes expand when cultured in presence of islets from NOD-scid donors
|
|
|
• transgenic CTLs generated in culture on islets exhibit cytotoxicity against a NOD-derived beta cell adenoma cell line and this is augmented when adenoma cells are pretreated with IFNG
|
|
|
• female NOD mice carrying both transgenes develop IDDM at a greatly increased rate compared to nontransgenic controls with disease appearing as early as 3 weeks of age
|
hematopoietic system
|
|
• T cells expressing the transgenes comprise ~35% of the total peripheral blood lymphocyte population, a significant fraction of these T cells resides in the CD4 lineage rather than in the expected CD8 lineage
|
|
|
• only transgene expressing CD8+ T cells from primary splenocytes expand when cultured in presence of islets from NOD-scid donors
|
|
|
• transgenic CTLs generated in culture on islets exhibit cytotoxicity against a NOD-derived beta cell adenoma cell line and this is augmented when adenoma cells are pretreated with IFNG
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(TcrbAI4)1Dvs mutation
(4 available)
|
|
|
hematopoietic system
|
|
• T cells expressing the transgene comprise ~22% of the total peripheral blood lymphocyte population, a significantly higher fraction of these T cells resides in the CD4 lineage rather than in the expected CD8 lineage
|
homeostasis/metabolism
immune system
|
|
• T cells expressing the transgene comprise ~22% of the total peripheral blood lymphocyte population, a significantly higher fraction of these T cells resides in the CD4 lineage rather than in the expected CD8 lineage
|
Analysis Tools